RPCI-UPCI Ovarian Cancer SPORE
RPCI-UPCI Ovarian Cancer SPORE
批准号:
9111874
负责人:
KUNLE O. ODUNSI
金额:
$41.18万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-18 至 2019-06-30
关键词:
AddressAntigensAreaAutologousAvidityBiological MarkersBiometryCD8B1 geneCancer PatientCancer PrognosisCellsClassificationClinical ResearchClinical TrialsCollaborationsCommunitiesDataDendritic CellsDevelopmentDiagnosisDioxygenasesDisciplineDisease MarkerDisease remissionEnvironmentEnzymesEpithelial ovarian cancerEtiologyFosteringGenerationsGoalsGuidelinesHistologicImmuneImmune ToleranceImmune systemImmunityImmunologic MonitoringImmunosuppressive AgentsIndividualInfiltrationInvestigationK-Series Research Career ProgramsLeadLymphocyteMHC Class I GenesMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMedical InformaticsMemoryMentorsMeta-AnalysisMorbidity - disease rateMyelogenousOperative Surgical ProceduresOutcomeParticipantPathway interactionsPatientsPilot ProjectsPredictive ValuePreventionPropertyPublic HealthRecruitment ActivityRecurrenceRecurrent diseaseRegimenRelapseResearchResearch PersonnelResearch Project GrantsResistanceResourcesRiskRisk AssessmentRoswell Park Cancer InstituteScientistStagingSuppressor-Effector T-LymphocytesT cell therapyT-LymphocyteTestingTherapeuticTrainingTranslational ResearchTranslational Research Working GroupTranslationsTryptophan 2,3 DioxygenaseTumor BurdenUniversitiesUniversity of Pittsburgh Cancer InstituteVaccinesWomananticancer researchbasecancer therapycareercareer developmentchemotherapyclinical practicecombinatorialconditioningdesignhigh riskimprovedimproved outcomeindoleamineinhibitor/antagonistinnovationinter-institutionalinterestintraepithelialmTOR inhibitionmortalitynovelnovel markernovel strategiesnovel therapeuticsoutcome forecastovarian cancer preventionovarian neoplasmpopulation basedprognosticprogramspublic health relevanceresearch and developmentresponsetargeted treatmenttherapeutic biomarkertreatment stratificationtumorvaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of the University of the Roswell Park Cancer Institute (RPCI) and University of Pittsburgh (UPCI) Ovarian Cancer SPORE is to reduce the morbidity and mortality of ovarian cancer through innovative translational research. It includes four individual research projects, four supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at risk stratification, treatment
of primary and recurrent ovarian cancer, and prevention of relapse in patients in remission. The four projects have been carefully designed to have significant potential to change clinical practice paradigms in ovarian cancer within five years. The theme of the program uniquely reflects immune based approaches in the etiology, prognosis and treatment of patients with ovarian cancer. The proposed projects will: 1) Test a novel therapeutic strategy to break indoleamine 2,3-dioxygenase (IDO)-mediated immune tolerance in ovarian cancer, while inducing anti-tumor-specific immunity in patients in second remission (Project 1); 2) Test a combinatorial strategy of mTOR inhibition and IL-21 for ex-vivo conditioning of antigen stimulated CD8+ T cells for effector and memory functional attributes; and test whether the ex vivo generated cells produce durable immunity against ovarian tumor in a clinical trial (Project 2); 3) Test whether autologous tumor-loaded type-1-polarized dendritic cells (¿DC1s) will generate CTLs capable of recognizing ovarian cancer in either MHC class I-restricted- or MHC class l-unrestricted fashion; when used both as a vaccine and for adoptive T cell therapy (Project 3); Determine the predictive significance of myeloid derived suppressor cells (MDSCs), which have strong immunosuppressive properties in the long term survival of ovarian cancer patients (Project 4). Each project addresses at least one of the translational areas outlined in the SPORE guidelines and together, the program addresses the translational pathways defined by the Translational Research Working Group. Four Cores will support these projects: Administration, Biospecimen, Biostatistics and Medical Informatics, Immune Monitoring. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in ovarian cancer. The Developmental Research Program and the Career Developmental Program will provide a framework to mentor young investigators to develop careers in ovarian cancer translational research, and to fertilize testing of high risk, potentiall paradigm changing projects with translational potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RPCI-UPCI Ovarian Cancer SPORE
-
批准号:8472863
-
项目类别:
-
资助金额:$215.05万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Administrative Core
-
批准号:8485814
-
项目类别:
-
资助金额:$17.12万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Administrative Core
-
批准号:10171143
-
项目类别:
-
资助金额:$31.06万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Project 1
-
批准号:10473673
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
RPCI-UPCI Ovarian Cancer SPORE
-
批准号:8918488
-
项目类别:
-
资助金额:$212.8万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
RPCI-UPCI Ovarian Cancer SPORE
-
批准号:8737201
-
项目类别:
-
资助金额:$216.2万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Project 1
-
批准号:10171147
-
项目类别:
-
资助金额:$29.53万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
RPCI-UPCI Ovarian Cancer SPORE
-
批准号:8975257
-
项目类别:
-
资助金额:$6.68万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Inhibition of indole-amine 2,3 dioxygenase to Enhance Ovarian Tumor Immunity
-
批准号:8485806
-
项目类别:
-
资助金额:$37.46万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Administrative Core
-
批准号:10473655
-
项目类别:
-
资助金额:$31.25万
-
财政年份:2013
-
负责人:KUNLE O. ODUNSI
-
依托单位:
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
-
批准号:8885730
-
项目类别:
-
资助金额:$34.71万
-
财政年份:2011
-
负责人:KUNLE O. ODUNSI
-
依托单位:
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
-
批准号:8515757
-
项目类别:
-
资助金额:$31.84万
-
财政年份:2011
-
负责人:KUNLE O. ODUNSI
-
依托单位:
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
-
批准号:8698342
-
项目类别:
-
资助金额:$33.26万
-
财政年份:2011
-
负责人:KUNLE O. ODUNSI
-
依托单位:
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
-
批准号:8193621
-
项目类别:
-
资助金额:$33.04万
-
财政年份:2011
-
负责人:KUNLE O. ODUNSI
-
依托单位:
mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity
-
批准号:8326076
-
项目类别:
-
资助金额:$33.46万
-
财政年份:2011
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Post-doctoral research training in surgical oncology
-
批准号:9762852
-
项目类别:
-
资助金额:$21.11万
-
财政年份:2006
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Postdoctoral Research Training in Surgical Oncology
-
批准号:8909074
-
项目类别:
-
资助金额:$10.86万
-
财政年份:2006
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Ovarian Cancer Detection Using H-NMR_Based Metabonomics
-
批准号:6872758
-
项目类别:
-
资助金额:$18.33万
-
财政年份:2005
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Ovarian Cancer Detection Using H-NMR_Based Metabonomics
-
批准号:7051475
-
项目类别:
-
资助金额:$18.12万
-
财政年份:2005
-
负责人:KUNLE O. ODUNSI
-
依托单位:
Cancer Center Support Grant
-
批准号:9904497
-
项目类别:
-
资助金额:$446.85万
-
财政年份:1997
-
负责人:KUNLE O. ODUNSI
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: